Post-Polyp Detection, CRC Risk ID'd by Colonoscopy Factors

Share this article:
Post-Polyp Detection, CRC Risk ID'd by Colonoscopy Factors
Post-Polyp Detection, CRC Risk ID'd by Colonoscopy Factors

(HealthDay News) -- In the community setting, after colonoscopic polyp detection, colonoscopy-related factors such as incomplete polyp removal and lack of surveillance colonoscopies are more important than polyp characteristics in predicting subsequent colorectal cancer (CRC) risk, according to a study published in the Aug. 21 issue of the Annals of Internal Medicine.

To examine the role of colonoscopy-related factors and polyp characteristics on the risk for CRC after detection of colonoscopic polyps, Hermann Brenner, M.D., M.P.H., of the German Cancer Research Center in Heidelberg, and colleagues used data from a previously published population-based, case-control study involving 3,148 case participants with CRC and 3,274 control patients.

The researchers identified 155 case participants and 260 control participants with physician-validated polyp detection in the preceding 10 years. Among cases, characteristics that were significantly more common included: incomplete removal of all polyps (odds ratio [OR], 3.73); no surveillance colonoscopy within five years (OR, 2.96); and detection of three or more polyps (OR, 2.21). Overall, nearly twice as many CRC cases were due to colonoscopy-related rather than polyp-related characteristics (41.1 versus 21.7 percent).

"We found colonoscopy-related factors (in particular, lack of complete removal of all polyps and lack of surveillance colonoscopy within five years) to be more important predictors of CRC occurrence after colonoscopic detection of polyps (other than hyperplastic polyps) than polyp characteristics," the authors conclude.

Full Text (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.

Overdetection of PSA recurrence after radical prostatectomy more likely in older patients

Overdetection of PSA recurrence after radical prostatectomy more ...

For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.